Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
November 07, 2022 07:30 ET | Atsena Therapeutics
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena logo.jpg
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)  
October 03, 2022 07:30 ET | Atsena Therapeutics
ATSN-101 demonstrated clinically meaningful improvements in vision with no drug-related serious adverse events Data presented at the American Academy of Ophthalmology 2022 Annual Meeting DURHAM,...
Atsena logo.jpg
Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
September 21, 2022 07:30 ET | Atsena Therapeutics
Data from Phase I/II trial of ATSN-101 in patients with GUCY2D-associated Leber congenital amaurosis (LCA1) to be presented DURHAM, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a...
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
July 27, 2022 07:30 ET | Atsena Therapeutics
DURHAM, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena logo.jpg
Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting
May 02, 2022 07:30 ET | Atsena Therapeutics
DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids
October 18, 2021 07:15 ET | Atsena Therapeutics
Subretinal delivery of RS1 using AAV capsid that spreads laterally beyond the injection site overcomes challenges associated with intravitreal delivery DURHAM, N.C., Oct. 18, 2021 (GLOBE NEWSWIRE)...
Atsena Therapeutics Appoints Linda B. Couto, PhD, as Chief Scientific Officer
August 16, 2021 07:30 ET | Atsena Therapeutics
DURHAM, N.C., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena logo.jpg
Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors
July 12, 2021 07:30 ET | Atsena Therapeutics
DURHAM, N.C., July 12, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena logo.jpg
Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1
June 28, 2021 07:30 ET | Atsena Therapeutics
DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Appoints Kenji Fujita, MD, as Chief Medical Officer
June 14, 2021 07:30 ET | Atsena Therapeutics
DURHAM, N.C., June 14, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...